Site-specific PEGylation of lidamycin and its antitumor activity  by Li, Liang et al.
Institute of Materia Medica, Chinese Academy of Medical Sciences
H O S T E D  B Y Chinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2015;5(3):264–269http://dx.doi.org/10.10
2211-3835 & 2015 Ch
Elsevier B.V. This is
Abbreviations: ADC
CSF, granulocyte colo
Bertani; LDM, lidam
stimulating factor; rLD
nCorresponding aut
E-mail address: sh
Peer review under rwww.sciencedirect.comORIGINAL ARTICLESite-speciﬁc PEGylation of lidamycin and its
antitumor activityLiang Li, Boyang Shang, Lei Hu, Rongguang Shaon, Yongsu ZhennInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College,
Beijing 100050, China
Received 27 November 2014; received in revised form 18 December 2014; accepted 24 December 2014KEY WORDS
Enediyne antibiotic;
Polyethylene glycol;
Site-speciﬁc PEGylation;
Lidamycin16/j.apsb.2015.03.00
inese Pharmaceutica
an open access artic
s, antibody drug co
ny stimulating facto
ycin; mPEG-ALD,
P, recombinant lida
hors. Tel.: þ86 10 6
aor@bbn.cn (Rong
esponsibility of InstAbstract In this study, N-terminal site-speciﬁc mono-PEGylation of the recombinant lidamycin
apoprotein (rLDP) of lidamycin (LDM) was prepared using a polyethyleneglycol (PEG) derivative (Mw
20 kDa) through a reactive terminal aldehyde group under weak acidic conditions (pH 5.5). The
biochemical properties of mPEG-rLDP-AE, an enediyne-integrated conjugate, were analyzed by SDS-
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similar to that of native LDP. It is of interest that the PEGylation did not diminish the antitumor efﬁcacy
of LDM, implying the possibility that this derivative may function as a payload to deliver novel tumor-
targeted drugs.
& 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).6
l Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
njugates; AE, active enediyne; Anti-TNF Fab0, anti-tumor necrosis factor Fab0; DMSO, dimethyl sulfoxide; G-
r; IC50 values, half-inhibitory concentrations; IFN, interferon; IPTG, isopropyl-β-D-thiogalactoside; LB, Luria-
methoxy-PEG-propionaldehyde; PEG, polyethyleneglycol; rhG-CSF, recombinant human granulocyte colony
mycin apoprotein; SEC-HPLC, size-exclusion high-performance liquid chromatography
3026956; fax: þ86 10 63017302.
guang Shao).
itute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
Site-speciﬁc PEGylation of lidamycin and its antitumor activity 2651. Introduction
Lidamycin (LDM, also called C-1027) is a chromoprotein
enediyne antitumor antibiotic produced by Streptomyces globis-
porus C-1027 which was found by screening with spermatogonial
assay. This compound consists of a nine-membered cyclic active
enediyne (AE) chromophore and a noncovalent bound apoprotein
(LDP)1–3. Meanwhile, AE and LDP can be dissociated and
reconstituted in vitro4. LDM can induce DNA single-strand breaks
and double-strand breaks5,6, generating free radicals that abstract
hydrogen atoms from the backbone of DNA while undergoing a
Bergman cycloaromatization reaction7. LDM shows extremely
potent cytotoxicity toward cultured cancer cells with nanomolar
IC50 values and displays high efﬁcacy against a variety of murine
transplantable tumors and human cancer xenografts, including
glioma, multiple myeloma, and the cancers of breast, pancreas,
colon, lung, stomach and liver8. Furthermore, LDM is highly
active against multidrug-resistant cancer cells9. With potencies
several orders of magnitude higher than conventional chemothe-
rapeutics, LDM showed exceptional promise as new payload in the
study of antitumor therapeutic agents.
PEGylation, representing the covalent linkage of polyethylene-
glycol (PEG) to accessible amino residues of bioactive substances,
has become a major approach for overcoming most of the
biologics' limits, such as fast degradation by proteases, glomerular
ﬁltration in the kidney and antigenic response. The efﬁcacy of
PEGylation is evidenced by the clinical efﬁcacy of many
PEGylated proteins that are on the market or in late-stage clinical
trials10–12. The pharmacological properties of many protein
therapeutics, including interferon (IFN), granulocyte colony sti-
mulating factor (G-CSF), anti-tumor necrosis factor Fab0 (anti-
TNF Fab0) and uricase, can be improved by modiﬁcation of the
proteins with PEG derivatives12. Considering the versatile PEGy-
lated strategies in development, N-terminal site-speciﬁc PEGyla-
tion is increasingly dominating the development of mono-
PEGylated protein13, based on the fact that primary amine residues
in protein have different pKa 7.8 for the N-terminal α-amino group
and 10.1 for the ε-amino group in lysine residues14. For example,
Neulastas, produced by the attachment of a 20 kDa mPEG ALD
molecule to the α-amino group of the N-terminal methionine
residue of rhG-CSF, has already been successful in clinical use15.
In our previous work, recombinant LDP (rLDP) has been
successfully constructed and expressed in Escherichia coli through
recombinant DNA technology, which has similar activity to that of
native LDP. In this study, we PEGylated the N-terminus of rLDP
in a site-speciﬁc manner using mPEG ALD derivative (Mw
20 kDa). The site-speciﬁc PEGylated rLDP was characterized by
various analytical methods and then assembled with AE, which
was separated from LDM, to form an enediyne-energized analog,
PEG-rLDP-AE. In vitro, the cytotoxicity of mPEG-rLDP-AE
against several cancer cell lines was evaluated by MTT assays,
and in vivo antitumor efﬁcacy was assessed using the nude mouse
xenograft model.2. Materials and methods
2.1. Chemicals and cell culture
LDM, preserved by our laboratory, was isolated from S. globis-
porus C-1027. The mPEG-propionaldehyde (20 kDa) was pur-
chased from Beijing Kaizheng Biotech Development Co., Ltd.,and HPLC grade acetonitrile and formic acid were purchased from
Thermo Fisher Scientiﬁc, Inc. Other chemicals were purchased
from J & K Scientiﬁc Ltd.
MCF-7 (human mammary adenocarcinoma) cells, PG-BE1
(human lung giant cell carcinoma) cells, SW1990 (human pancreas
adenocarcinoma) cells and HepG2 (human liver carcinoma) cells
were grown in RPMI 1640 medium supplemented with 10% fetal
newborn bovine serum, 2 mmol/L L-glutamine, 100 U/mL peni-
cillin and 100 μg/mL streptomycin, and cultured at 37 1C in a
humidiﬁed atmosphere containing 5% CO2.2.2. Expression of rLDP
As previously reported16, 1 L Luria-Bertani (LB) medium contain-
ing 50 mg/L kanamycin was inoculated with 50 mL of a starter
culture that contained an overnight culture of the rLDP-expressing
strain. The inoculated medium was then maintained at 37 1C with
shaking at 220 rpm, and recombinant protein expression was
induced with isopropyl-β-D-thiogalactoside (IPTG) at an optical
density at 600 nm of 1.0. After 8 h of induction, the culture was
harvested by centrifugation, and the periplasmic fractions of the
collected culture were prepared by the osmotic shock method and
puriﬁed with a Ni2þ afﬁnity column.2.3. Preparation of mPEG-rLDP
The mPEG-propionaldehyde derivative (Mw 20 kDa) and rLDP
(molar ratio¼5:1) were dissolved in sodium acetate buffer
(50 mmol/L, pH 5.5) in the presence of sodium borohydride
(2.5 mmol/L) as a reducing agent. The PEGylation reaction was
conducted for 24 h at room temperature and the excess reducing
agent was removed by repeated ultraﬁltration using a centrifugal
ﬁlter with MWCO 10 kDa (Merck Millipore, USA), followed by
lyophilization with an Alpha 1-4LD Plus freeze dryer (Martin
Christ, Germany) to give crude mPEG-rLDP.2.4. Puriﬁcation and characterization of mPEG-rLDP and its
enediyne-energized analog
The crude mixture of mPEG-rLDP and excess mPEG-propionaldehyde
derivative was loaded onto a G75 sephadex gel ﬁltration column pre-
equilibrated with 20 mmol/L sodium acetate, pH 5.5, at a ﬂow rate of
1.0 mL/min. The fractions were analyzed by size-exclusion high-
performance liquid chromatography (SEC-HPLC, Agilent 1200 series)
equipped with a manual injector on a TSK G2000SWXL gel ﬁltration
column (300 mm 7.8 mm, 5 mm particle size) (Tosoh, Tokyo,
Japan); 20 μL of the sample was loaded into the column; an isocratic
mobile phase with 20 mmol/L PBS, pH 7.4; a ﬂow rate of 0.8 mL/min;
UV detection at 280 nm. The fractions containing mPEG-rLDP were
collected, pooled, desalted and lyophilized to produce the aimed
mPEG-rLDP and then the samples were stored at 20 1C.
The active AE was separated from LDM by using C4 pre-column
(250 mm 10 mm, 5 mm particle size) (Phenomenex, Torrance,
USA) with a 22% acetonitrile in 0.025% triﬂuoroactic acid mobile
phase. The AE solution was added to PBS (10 mmol/L, pH 7.4)
containing mPEG-rLDP, with the molecular ratio of 3:1, and was
incubated at 4 1C for 12 h while shaking. Free AE was removed by
repeated ultraﬁltration using a centrifugal ﬁlter with MWCO
(1000 Da). The assembled enediyne-energized mPEG-rLDP-AE
was conﬁrmed by HPLC equipped with a Jupiter C4 column
Liang Li et al.266(250 mm 4.6 mm, 5 mm particle size) (Phenomenex, Torrance,
USA). Absorbance at 340 nm and 214 nm was measured.
2.5. Cytotoxicity assay
Antiproliferative effect of mPEG-rLDP-AE was evaluated using
MTT assay. Adherent cells were seeded into 96-well plates
(Costar, Cambridge, Mass.) at (4–5) 103 cells/well, depending
on the cell lines, in 180 μL of medium and incubated for 24 h.
Cells were treated with various concentrations of mPEG-rLDP-AE
in 200 μL of medium for 48 h. After the treatment periods, the
supernatant medium was decanted and 20 μL of 5 mg/mL MTT in
PBS was added. Then cells were incubated for another 4 h.
Finally, culture medium was removed from each well, and
formazan was dissolved with 150 μL of dimethyl sulfoxide
(DMSO). The absorbance was quantitated by a Microplate Reader
(Multiskan MK3, Thermo Labsystem, USA) at 570 nm. Survival
ratio was calculated according to the following formula:
Survival ratio (%)¼ (AtestAblank)/(AcontrolAblank) 100.
2.6. In vivo antitumor efﬁcacy
The PG-BE1 human lung cancer cell line was grown as a
subcutaneous xenograft in female athymic nude mice (nu/nu), 6–
8 weeks old, by injecting 5 106 cells in each ﬂank. Mice with
established tumors corresponding to a mean volume of 2–3 mm3 in
diameter were randomized into groups (6 animals each) in a
manner that minimized the difference in tumor size between the
groups. Each animal received vehicle control, LDM, mPEG-rLDP
and mPEG-rLDP-AE, respectively by intravenous injection onceFigure 1 The characterization of rLDP. (A) SDS-PAGE analysis of the mPE
analysis of rLDP was performed on a TSK G2000SWXL column at ambient te
with a ﬂow rate of 0.8 mL/min and a detection wavelength of 280 nm. (C) MAevery two weeks. The doses of mPEG-rLDP-AE were 0.075, 0.15
and 0.3 mg/kg, respectively. The mice were weighed and tumor
sizes were measured with a vernier caliper and recorded twice a
week. Tumor volume was calculated using the formula: a b2/2,
where a was the longer diameter and b was the perpendicular
shorter diameter.2.7. Statistical analysis
Data were expressed as mean7standard error (X7SE). Statistical
analysis was performed using SPSS. Statistical signiﬁcance was
assessed by the Student's t-test, and P values less than 0.05 were
considered to be statistically signiﬁcant.3. Result
3.1. Preparation and characterization of rLDP
The DNA fragment encoding rLDP was cloned and inserted into
the pET30a expression vector. SDS-PAGE was used to detect the
expression of fusion proteins. The results showed that fusion
protein rLDP was expressed (Fig. 1A). The rLDP was puriﬁed
using immobilized metal-afﬁnity chromatography resin under
denaturing conditions and the target rLDP was obtained in over
95% purity (Fig. 1B). The rLDP, an E. coli–expressed (His)6-
tagged protein, with a molecular mass of approximately 11.7 kDa
is determined by MALDI-TOF mass spectrometry (Fig. 1C). The
rLDP with conﬁrmed physicochemical characteristics and theG-rLDP and rLDP samples stained with Coomassie Blue. (B) SEC-HPLC
mperature. The mobile phase was 20 mmol/L sodium phosphate (pH 7.4)
LDI-TOF spectra of rLDP. The molecular weight of rLDP was 11,692 Da.
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(Fig. 2A).3.2. PEGylated rLDP and its enediyne-energized analog
The native LDP has 110 amino acids and two disulﬁde bonds.
There are many potential PEGylation sites in rLDP including
several ε-amine groups of lysine and one α-amino group at the N-
terminus. The methoxy-PEG-ALD (Mw 20 kDa) was conjugated
under acidic conditions (pH 5.5) for 24 h, and the conjugated
mixture was analyzed by SEC-HPLC on a TSK G2000SWXL gel
ﬁltration column (Fig. 2A). Chromatography results showed that
mono-PEGylated rLDP was predominantly produced when using
PEG-propionaldehyde derivative. It was also noted that mono-
PEGylated rLDP could be readily separated from the unPEGylated
rLDP fraction by a SEC gel ﬁltration column (Fig. 2B). Use of the
G75 sephadex gel ﬁltration column was sufﬁcient to successfully
purify the mono-PEGylated rLDP fraction. The unconjugated,
activated mPEG-ALD and rLDP were removed by ongoing
chromatographic separation processes.
To estimate the molecular weight distribution of PEGylated
rLDP, MALDI-TOF mass spectrometry was used to further
conﬁrm the SEC-HPLC results (Fig. 2C). Mass value is expressed
as Mp (the most probable mass peak) for the mPEG-rLDP. The
measured mass-to-charge ratio was 33,231 m/z (16,607 m/2z) for
mPEG-rLDP without showing any other mass peaks. Considering
the molecular weights of rLDP (11.7 kDa) and PEGs (20 kDa), the
obtained mass of the conjugate was very consistent with the
calculated mass sum of individual molecules.
The energized mPEG-rLDP-AE was prepared by integrating AE
molecule of LDM into mPEG-rLDP conjugate. Data from reverse-
phase HPLC showed that AE molecule was successfully integratedFigure 2 The physicochemical characters of mPEG-rLDP. (A) SEC-HPLC
TSK G2000SWXL column at ambient temperature. The mobile phase was 2
and a detection wavelength of 280 nm. (B) SEC-HPLC analysis of mPEG-
molecular weight of mPEG-rLDP was 33,231 Da. (D) Analysis of mPEG
column at 340 nm.into mPEG-rLDP (Fig. 2D), which implies that mPEG-rLDP keeps
native LDP structure in the PEGylation modiﬁed product.
3.3. In vitro cytotoxicity of mPEG-rLDP-AE
The cytotoxicity of mPEG-rLDP-AE and LDM against four
different cell lines was determined using MTT assays. As shown
in Table 1, both unmodiﬁed LDM and PEGylated LDM (mPEG-
rLDP-AE) showed highly potent growth inhibitory effects, judging
from their half-inhibitory concentrations (IC50 values). The unmo-
diﬁed LDM showed IC50 values ranging from 0.1 nmol/L to
4.2 nmol/L, while the IC50 values ranged from 0.03 nmol/L to
1 nmol/L for the PEGylated LDM. As shown in Figs. 1A and B,
and 2A, mPEG-rLDP still retained the binding capability to AE
and presented similar physicochemical characteristics to that of
native LDP. Furthermore, the PEGylation did not diminish the
antitumor efﬁcacy of LDM.
3.4. Therapeutic efﬁcacy of mPEG-rLDP-AE
The antitumor activity of mPEG-rLDP-AE was investigated in
nude mice with an established human lung cancer PG-BE1
xenograft. Tumor-bearing athymic mice were treated with LDM,
mPEG-rLDP-AE and mPEG-rLDP. LDM at the tolerated dose of
0.05 mg/kg showed a tumor inhibitory rate of 76.9%. The mPEG-
rLDP-AE at 0.3 mg/kg suppressed the tumor growth by 82.8%,
while mPEG-rLDP at 20 mg/kg did not show signiﬁcant the-
rapeutic efﬁcacy (Fig. 3A). No obvious toxic effects were
observed in all groups during the experiment. These results
suggested that both mPEG-rLDP-AE and LDM could retard the
growth of PG-BE1 xenografts signiﬁcantly in nude mice. Body
weight loss resulted from the enediyne energized mPEG-rLDP-AEanalysis of mPEG and rLDP conjugated mixture was performed on a
0 mmol/L sodium phosphate (pH 7.4) with a ﬂow rate of 0.8 mL/min
rLDP after puriﬁcation. (C) MALDI-TOF spectra of mPEG-rLDP. The
-rLDP and mPEG-rLDP-AE determined by RP-HPLC on C4 300A
Table 1 Determined IC50 (nmol/L)
a values on different cancer cell lines.
Cell line HT-1080 SW1990 MCF-7 PG-BE1 HepG2
LDM 0.9870.03 0.5470.05 0.4270.05 0.5670.05 0.0970.04
mPEG-rLDP-AE 0.5570.08 0.3970.06 0.1170.02 0.2570.07 0.0370.01
aData are expressed as mean7SD, n¼6.
Figure 3 In vivo antitumor effect of mPEG-rLDP-AE on transplanted tumor. (A) Changes in tumor volume (Po0.05 vs. Control); (B) changes in
body weight of human lung cancer cell PG-BE1 xenograft-bearing mice.
Liang Li et al.268treatment in each group was also measured at the termination of
the experiment, in which all groups except mPEG-rLDP-AE
treated group did not exceed 10% of the pretreatment weights
(Fig. 3B). No deaths were found in any of the treated groups.4. Discussion
Based on our previous reports that the rLDP has been successfully
expressed in E. coli and shows the binding activity similar to that
of native LDP, the present study developed a simple preparation
method for N-terminal site-speciﬁc mono-PEGylated LDM which
still retains its highly potent cytotoxicity. In this study, the PEG
derivative was a methoxy-PEG-ALD having the average Mw of
20 kDa. The RP-HPLC result in Fig. 2 and antiproliferative effect
of mPEG-rLDP-AE suggest that N-terminal PEGylation did not
hinder the binding capacity of AE to rLDP, because the N-terminal
residue is located far from the AE binding pocket in rLDP. The
conjugation of mPEG-ALD to the primary amine groups of rLDP
depends on the nucleophilic substitution reaction, with the attack-
ing of unprotonated amine group to the carbonyl groups of
aldehyde. Under basic conditions, all α- and ε-primary amines in
rLDP were equally reactive to the aldehyde. A heterogeneous
mixture of multi-site PEGylated rLDP may also be produced. In
contrast, under acidic conditions, unprotonated N-terminal
α-amine group (pKa value: 7–8) is more reactive than ε-amine
groups (pKa value: 10–11) in lysine residues, which possibly
resulted in the site-speciﬁc mono-PEGylated rLDP. This reductive
amination reaction with the N-terminal α-amine group, in the
presence of reducing agent, has also been reported in other
therapeutic protein PEGylated modiﬁcation17,18. After the simple
puriﬁcation steps of G75 sephadex gel ﬁltration column, the
puriﬁed mPEG-rLDP could be obtained by removing free
mPEG-ALD and unmodiﬁed rLDP as evidenced by the SDS-
PAGE, SEC-HPLC and MALDI-TOF analysis. The content of
rLDP protein in the mPEG-rLDP was measured by UV 280 nm.
These results not only indicated that mPEG-rLDP was pure, butalso adequately revealed that the molecular weights were in good
agreement with the rLDP conjugate containing a single 20 kDa
PEG derivative.
LDM is a highly potent antitumor antibiotic composed of LDP
and AE. Considering the extremely potent DNA-breaking activity,
LDM could be the attractive payload molecule for preparation of
tumor-targeted therapeutics, such as antibody drug conjugates
(ADCs), nanomedicines and target-active fusion proteins. Indeed,
several antibody-LDM conjugates, polymer conjugates, fusion
proteins and ligand oligopeptide-integrated fusion proteins have
been manufactured in previous reports, such as monoclonal
antibody-LDM conjugate (3G11-LDM), dextran-LDM conjugate
(Dex-rLDP-AE), bispeciﬁc enediyne-energized fusion protein (Ec-
LDP-Hr-AE) and tandem scFv-based enediyne-energized fusion
protein (dFv-LDP-AE)16,19–21. All these LDM-based tumor-tar-
geted drugs possessed highly potent cytotoxicity to cancer cells
and signiﬁcant antitumor efﬁcacy in vivo. The present results
indicated that mPEG-rLDP-AE (namely, mPEG-LDM) shows
signiﬁcant in vitro and in vivo antitumor activity. Interestingly,
unlike other proteins that are generally inactivated after PEGyla-
tion, the conjugate mPEG-rLDP still retains the binding capability
to AE and demonstrates the physicochemical characters similar to
that of native LDP. Therefore, the PEGylation did not diminish the
antitumor efﬁcacy of LDM and also showed the possibility as
payload to develop novel tumor-targeted drugs.5. Conclusions
In this study, mPEG-ALD was speciﬁcally conjugated at the N-
terminal α-amine group of rLDP in a weakly acidic environment.
The mPEG-rLDP still retained the AE-binding capacity and
mPEG-rLDP-AE showed highly potent cancer cells growth
inhibitory effects at nanomolar level. Meanwhile, the in vivo
antitumor activity of mPEG-rLDP-AE, investigated in nude mice
with established human lung cancer PG-BE1 xenograft, also
remained after modiﬁcation of the LDP with PEG. The results
Site-speciﬁc PEGylation of lidamycin and its antitumor activity 269suggested that PEGylation of rLDP could be a useful approach to
develop novel tumor-targeted drugs based on lidamycin.
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